Across TCGA pan-cancer cohorts, TAFA2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAFA2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TAFA2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TAFA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, PAAD, and ESCA are the cancer types where TAFA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.961	0.624	.015	26	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	.001	12	view →
LUAD	OS	Median	All	0.540	0.788	.021	2	view →
SKCM	OS	Median	II,III,IV	1.000	0.833	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TAFA2 tumor-vs-normal RNA expression · all TAFA2 data types